O Shaughnessy Asset Management LLC Boosts Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

O Shaughnessy Asset Management LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 6,876 shares of the company’s stock after purchasing an additional 639 shares during the period. O Shaughnessy Asset Management LLC’s holdings in IDEXX Laboratories were worth $3,713,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Nordea Investment Management AB lifted its holdings in IDEXX Laboratories by 15.5% during the first quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock worth $7,447,000 after buying an additional 1,839 shares during the period. Brevan Howard Capital Management LP purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $3,183,000. Assenagon Asset Management S.A. grew its stake in IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock valued at $24,196,000 after purchasing an additional 8,831 shares during the last quarter. Carderock Capital Management Inc. raised its holdings in IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after purchasing an additional 4,315 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in shares of IDEXX Laboratories by 9.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 42,045 shares of the company’s stock valued at $23,307,000 after buying an additional 3,627 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX traded down $4.88 during trading on Tuesday, hitting $470.41. The stock had a trading volume of 398,355 shares, compared to its average volume of 474,107. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The stock has a market capitalization of $38.85 billion, a price-to-earnings ratio of 45.54, a price-to-earnings-growth ratio of 3.83 and a beta of 1.32. The stock has a 50-day simple moving average of $499.04 and a two-hundred day simple moving average of $519.06.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The company had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Finally, Morgan Stanley dropped their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.